{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:50Z","timestamp":1787026370501,"version":"build-2736575974"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00190","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T01:00:38Z","timestamp":1586912438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Prospect of Sodium\u2013Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes"],"prefix":"10.3389","volume":"11","author":[{"given":"Yinqiu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangli","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.diabres.2014.11.004","article-title":"Quality of diabetes care in low- and middle-income Asian and Middle Eastern countries. (1993-2012): 20-year systematic review","volume":"107","author":"Shivashankar","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010","volume":"36","author":"Stark","year":"2013","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc08-9016","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4158\/EP.12.4.388","article-title":"Effects of duration of type 2 diabetes mellitus on insulin secretion","volume":"12","author":"Zangeneh","year":"2006","journal-title":"Endocr Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e6944","DOI":"10.1097\/MD.0000000000006944","article-title":"Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"7","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes. (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy. (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2818","DOI":"10.1002\/dmrr.2818","article-title":"Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis","volume":"33","author":"Min","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/jdi.12787","article-title":"Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: a systematic review with an indirect comparison meta-analysis","volume":"9","author":"Cho","year":"2018","journal-title":"J Diabetes Investig"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.2337\/dc17-0744","article-title":"When insulin therapy fails: the impact of SGLT2 inhibitors in patients with type 2 diabetes","volume":"40","author":"Harris","year":"2017","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/2230-8210.172278","article-title":"Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: a comparative review","volume":"20","author":"Singh","year":"2016","journal-title":"Indian J Endocrinol Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.2337\/dc13-3010","article-title":"Factors associated with weight gain in people with type 2 diabetes starting on insulin","volume":"37","author":"Balkau","year":"2014","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1463-1326.2011.01433.x","article-title":"Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis","volume":"13","author":"Pontiroli","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1463-1326.2004.00322.x","article-title":"Prevention of weight gain in type 2 diabetes requiring insulin treatment","volume":"6","author":"de Boer","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2165\/00002018-200427120-00002","article-title":"Combined thiazolidinedione-insulin therapy: should we be concerned about safety?","volume":"27","author":"Scheen","year":"2004","journal-title":"Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study. (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13300-016-0217-4","article-title":"Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis","volume":"8","author":"Lorenzi","year":"2017","journal-title":"Diabetes Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese. (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity."},{"key":"B30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"Ebiomedicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1152\/ajpendo.1979.237.3.E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/db10-1328","article-title":"SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function","volume":"60","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdi.13131","article-title":"Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"11","author":"Watada","year":"2020","journal-title":"J Diabetes Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs. (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00439-002-0820-5","article-title":"Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter. (SGLT2)","volume":"111","author":"van den Heuvel","year":"2002","journal-title":"Hum Genet."},{"key":"B40","first-page":"451","article-title":"Sodium-glucose linked transporter 2. (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview","volume":"40","author":"Mosley","year":"2015","journal-title":"P T"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fphar.2014.00274","article-title":"Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans","volume":"5","author":"Lu","year":"2014","journal-title":"Front Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/21623945.2017.1413516","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"B47","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.1964","article-title":"CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity","volume":"15","author":"Nishimura","year":"2009","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrendo.2012.114","article-title":"Adaptive immunity in obesity and insulin resistance","volume":"8","author":"Sell","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/hep.26607","article-title":"M2 kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease","volume":"59","author":"Wan","year":"2014","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cmet.2008.08.015","article-title":"Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals","volume":"8","author":"Patsouris","year":"2008","journal-title":"Cell Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e54615","DOI":"10.1371\/journal.pone.0054615","article-title":"Association between serum leptin concentrations and insulin resistance: a population-based study from China","volume":"8","author":"Zuo","year":"2013","journal-title":"PLoS ONE"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1161\/01.ATV.20.6.1595","article-title":"Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients","volume":"20","author":"Hotta","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1210\/en.2013-1191","article-title":"Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice","volume":"154","author":"Camporez","year":"2013","journal-title":"Endocrinology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","article-title":"Role of leptin and adiponectin in insulin resistance","volume":"417","author":"Yadav","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jphs.2016.06.004","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: part 2. Antidiabetic effects in type 2 diabetic mice","volume":"131","author":"Tahara","year":"2016","journal-title":"J Pharmacol Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1111\/dom.13400","article-title":"Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic beta-cells in db\/db mice: the earlier and longer, the better","volume":"20","author":"Kimura","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B63","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.bbrc.2015.10.038","article-title":"Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key beta-cell factors under diabetic conditions","volume":"467","author":"Shimo","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/dom.13743","article-title":"Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B67","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2. (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"B68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"B70","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2215\/CJN.10180916","article-title":"Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diabet Vascul Dis Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1161\/01.CIR.102.25.3032","article-title":"Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial Guard during ischemia against necrosis. (GUARDIAN) Investigators","volume":"102","author":"Theroux","year":"2000","journal-title":"Circulation"},{"key":"B73","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"B74","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 inhibitors in heart failure: diabetes and beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"B76","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2. (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/ehjcvp\/pvw009","article-title":"Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects","volume":"2","author":"de Leeuw","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1172\/JCI92450","article-title":"Neutrophil-derived S100 calcium-binding proteins A8\/A9 promote reticulated thrombocytosis and atherogenesis in diabetes","volume":"127","author":"Kraakman","year":"2017","journal-title":"J Clin Invest"},{"key":"B80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S2213-8587(15)00204-1","article-title":"SGLT inhibition and euglycaemic diabetic ketoacidosis","volume":"3","author":"Hine","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"B83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bone.2016.10.026","article-title":"The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes","volume":"94","author":"Thrailkill","year":"2017","journal-title":"Bone"},{"key":"B84","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","article-title":"SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice","volume":"82","author":"Thrailkill","year":"2016","journal-title":"Bone"},{"key":"B86","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B88","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy. (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabet Obes Metab"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e2903","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2. (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2. (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T01:00:40Z","timestamp":1586912440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":90,"alternative-id":["10.3389\/fendo.2020.00190"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00190","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"article-number":"190"}}